Coherus BioSciences, Inc. | Coherus Announces FDA Approval of UDENYCA
https://investors.coherus.com/news-releases/news-release-details/coherus-announces-fda-approval-udenyca-onbodytm-novel-and
WebDec 26, 2023 · UDENYCA ® is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
DA: 57 PA: 9 MOZ Rank: 95